S. 5244: Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act
This bill would make major changes to the federal 340B drug discount program, which lets certain hospitals, clinics, and other covered providers buy outpatient drugs at reduced prices.
Core changes to the 340B program
The bill would tighten the rules on who can use the program and how drugs can be dispensed. It would:
- Define who counts as a patient for 340B purposes and clarify when a prescription is considered a referral prescription.
- Set rules for contract pharmacies that dispense drugs on behalf of covered entities, including registration and verification requirements.
- Allow certain use of contract pharmacies and pharmacies wholly owned by a covered entity, but under stricter oversight.
- Place limits intended to prevent duplicate discounts and drug diversion, meaning a drug would not improperly receive more than one government discount and would not be sold or used outside the program’s allowed channels.
Oversight, reporting, and transparency
The bill would add substantial reporting and accountability requirements. It would create a 340B data clearinghouse to help track discounts and reduce duplicate billing or discounts. It would also require:
- More detailed recordkeeping for covered entities and contract pharmacies.
- Public posting of certain program data.
- Transparency in patient financial assistance policies.
- Verification of contracts and other arrangements involving pharmacies and covered entities.
- Regular audits and stronger enforcement authority for noncompliance.
Rules for child sites and related arrangements
The bill would make it harder for additional locations, often called child sites, to qualify unless they meet strict eligibility and documentation requirements. It would also define these sites more clearly and require stronger proof that they are properly connected to a qualifying covered entity and are maintaining the required records.
Limits on manufacturer and intermediary interference
The bill would prohibit health plans and pharmacy benefit managers (PBMs) from interfering with how the 340B program is carried out or from discriminating against covered entities because they participate in the program. It would also impose obligations on drug manufacturers to comply with program rules and allow penalties for failure to do so.
Phasing out rebate pilot programs and adding fees
The bill would sunset certain rebate pilot programs, replacing or limiting them with the new compliance framework. It would also create a user fee program starting in 2031 to help fund oversight, audits, and enforcement activities.
Penalties and enforcement
Entities that do not follow the new rules could face penalties. The bill would give the government more tools to investigate compliance, conduct audits, and enforce the program’s requirements.
Relevant Companies
- CVS — CVS Health, through its pharmacy benefit manager and retail pharmacy operations, could be affected by new limits on PBM interference, reporting requirements, and contract pharmacy rules.
- CI — Cigna, through its PBM business, could be affected by restrictions on PBM practices and requirements related to 340B program administration.
- ELV — Elevance Health could be affected if its pharmacy benefit management or managed care operations must adjust to new 340B compliance and reporting rules.
- UNH — UnitedHealth Group, through Optum and its PBM and health services businesses, could be affected by new limits on PBM conduct and 340B-related oversight.
- WBA — Walgreens Boots Alliance could be affected by stricter contract-pharmacy registration, auditing, and transparency rules, since its pharmacies participate in 340B dispensing arrangements.
- None found
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
6 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Aug. 05, 2026 | Introduced in Senate |
| Aug. 05, 2026 | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.